Q1 closed at $2.14M in new bookings against a $2.40M target (89% attainment). While topline bookings fell short, the underlying signals are more nuanced than the headline suggests. Win rate improved 3pp quarter-over-quarter to 24.1%, and average deal size increased 11% to $68K — both indicators that deal quality is strengthening even as volume is soft. The miss was driven primarily by three factors: a 12pp drop in Orthopedics win rate tied to legal review bottlenecks, lower-than-expected marketing-sourced pipeline conversion, and two enterprise deals ($185K combined) that slipped to Q2 due to budget approval delays.
The recommendations in this review focus on the highest-leverage interventions: implementing a legal escalation protocol for proposals aging beyond 10 days, tightening ICP scoring on paid marketing leads, and reallocating territory coverage toward Dermatology where win rates and ACV significantly outperform the portfolio average.
| Metric | Q4 2024 | Q1 2025 | QoQ Change |
|---|---|---|---|
| Total Bookings | $1.98M | $2.14M | +8.1% |
| Target | $2.20M | $2.40M | |
| Attainment | 90% | 89% | -1pp |
| Deals Closed Won | 34 | 31 | -8.8% |
| Avg Deal Size (ACV) | $58.2K | $68.1K | +17.0% |
| Win Rate (Qual → Won) | 21.3% | 24.1% | +3pp |
| Avg Sales Cycle (days) | 52 | 48 | -7.7% |
| Qualified Pipeline (EoQ) | $6.8M | $7.2M | +5.9% |
| Pipeline Coverage Ratio | 2.8x | 3.0x | +0.2x |
Key takeaway: The bookings miss obscures improving fundamentals. Deal quality metrics (ACV, win rate, cycle time) are all trending positively. The volume gap is a sourcing issue, not an execution issue — we're converting pipeline at a higher rate but don't have enough of it at the top of the funnel.
| Specialty | Deals Won | Won ACV | Win Rate | Avg Cycle | vs. Q4 |
|---|---|---|---|---|---|
| Dermatology | 12 | $892K | 34.2% | 38d | ▲ +6pp |
| Gastroenterology | 8 | $498K | 26.1% | 44d | ▲ +2pp |
| Ophthalmology | 7 | $421K | 22.8% | 51d | → flat |
| Orthopedics | 4 | $329K | 14.3% | 62d | ▼ -12pp |
Dermatology is the standout. At a 34.2% win rate with a 38-day average cycle, Derm practices are closing faster and at higher rates than any other segment. They also represent the highest ACV concentration ($892K on just 12 deals, averaging $74K per deal). Currently, only 2 of our 6 reps have significant Derm territory coverage — this represents a clear reallocation opportunity.
Orthopedics requires immediate attention. Win rate dropped from 26.3% in Q4 to 14.3% in Q1. Root cause analysis shows this is not a product-market fit issue — it's a process bottleneck. Three of five lost Ortho deals had proposals stuck in legal review for 20+ days (median for Won deals is 6 days). When we exclude the legal-delayed losses, the adjusted Ortho win rate is 22.1% — in line with historical performance.
| Source | Leads | Opps Created | Pipeline $ | Won $ | Source Win Rate |
|---|---|---|---|---|---|
| Referral | 42 | 28 | $1.9M | $680K | 35.7% |
| Inbound Organic | 156 | 34 | $2.1M | $520K | 22.4% |
| Trade Show (HIMSS, AAD) | 68 | 18 | $1.4M | $410K | 27.8% |
| Outbound SDR | 234 | 22 | $1.2M | $340K | 18.2% |
| Paid (Search + Social) | 312 | 14 | $0.6M | $190K | 14.3% |
Referrals continue to outperform every other channel with a 35.7% win rate and the highest ACV per deal. This is not surprising — referred prospects arrive with pre-existing trust and shorter evaluation cycles. What is notable is that we have no structured referral program in place. Even a modest program that increases referral volume by 20% would project to an additional $136K in quarterly bookings at current conversion rates.
Paid channels are underperforming on conversion. Paid search and social generated the highest lead volume (312 leads) but the lowest win rate (14.3%) and smallest pipeline contribution ($600K). The issue is upstream: paid leads are converting to opportunity at 4.5% vs. 21.8% for inbound organic. ICP fit scoring on paid leads shows 62% of paid leads fall below our ideal customer profile threshold, compared to 28% for organic. We're generating volume, not quality.
| Rep | Quota | Attainment | Deals Won | Avg ACV | Avg Cycle | Pipeline |
|---|---|---|---|---|---|---|
| Chen | $450K | 112% | 8 | $63K | 41d | $1.4M |
| Rivera | $450K | 84% | 6 | $63K | 52d | $980K |
| Okafor | $400K | 95% | 6 | $63K | 44d | $1.1M |
| Patel | $350K | 78% | 4 | $68K | 58d | $720K |
| Wong | $400K | 89% | 5 | $71K | 46d | $1.0M |
| Kim | $350K | 81% | 2 | $142K | $68d | $1.2M |
Chen is the top performer at 112% attainment, driven by volume (8 deals) and the shortest average cycle (41 days). Her approach of front-loading demos early in the evaluation process is working — she averages 2.3 demos per closed deal vs. 3.1 for the team.
Kim presents an interesting case: lowest deal count (2) but highest ACV ($142K) and the most open pipeline ($1.2M). He's working larger enterprise deals with longer cycles. His 81% attainment is misleading — one of his two slipped Q2 deals ($110K) would have put him at 112%. His pipeline suggests a strong Q2.
Patel is below target at 78% with the longest average cycle (58 days). Diagnostic: 60% of his pipeline is Orthopedics, which is the segment hit hardest by the legal bottleneck. Adjusting for legal-delayed losses, his projected attainment would be ~92%. The issue is segment concentration, not rep performance.
| Specialty | Customers (Start) | Churned | Expanded | Churn Rate | NRR |
|---|---|---|---|---|---|
| Dermatology | 248 | 8 | 32 | 3.2% | 112.4% |
| Orthopedics | 186 | 14 | 18 | 7.5% | 103.8% |
| Gastroenterology | 142 | 6 | 22 | 4.2% | 110.1% |
| Ophthalmology | 210 | 11 | 28 | 5.2% | 108.6% |
Blended NRR is 108.7% — our installed base is growing. However, the spread between specialties is significant. Dermatology NRR at 112.4% with only 3.2% churn is exceptional and reinforces the segment's attractiveness. Orthopedics churn at 7.5% is the outlier and warrants investigation. Exit survey data indicates "switched to competitor" as the primary reason (64% of churned Ortho accounts), suggesting product-competitive gaps in the orthopedic workflow specifically.
If I were running Q2, the sequencing matters as much as the actions. Week 1: ship the legal-escalation SLA. It is the highest-leverage zero-cost intervention and unlocks ~$180K of stranded Ortho pipeline immediately; nothing else here pays back faster. Week 2: reallocate one rep from general-territory coverage to Dermatology, with Chen mentoring the transition — her 41-day cycle and 8-deal quarter are the evidence base, and her demos-per-close ratio of 2.3 vs. the team's 3.1 is a teachable pattern. Week 4: launch the structured referral program. Referrals close at 35.7% vs. 14.3% for paid; we need to start refilling top-of-funnel with the channel that actually converts before paid-campaign ICP tightening reduces volume.
The bigger strategic bet: moving from "we serve all four specialties equally" to "we are the specialty EHR with the best Dermatology workflow in the market, and we win there." Every Q1 metric points the same direction — 34.2% Derm win rate, 112.4% NRR, 3.2% churn, $74K average ACV. The concentration risk is real: a credible Derm-focused entrant in the next 12 months turns our positioning from moat into vulnerability. We mitigate by feeding Ortho win/loss interview findings (P2) directly into the Product roadmap as soon as they land, closing the back door while we double down on the front one.
Pipeline coverage target for Q2: 3.5x against quota (up from 3.0x). Hitting that requires either growing top-of-funnel ~17% or improving conversion at the same volume. The four P0/P1 recommendations are designed to do both — referrals and paid ICP tightening lift top-of-funnel quality; legal SLA and territory reallocation lift conversion. If all four execute on schedule, the model projects $2.5–2.7M in Q2 bookings (vs. the $2.40M target) and exits Q2 with $8.4M in qualified pipeline.